

## CUTANA™ E. coli Spike-in DNA

|            |             |           |        |
|------------|-------------|-----------|--------|
| Catalog No | 18-1401     | Pack Size | 100 ng |
| Lot No     | 25342007-02 |           |        |

### DESCRIPTION

Fragmented DNA derived from *Escherichia coli* (*E. coli*) can be used as a spike-in control for experimental normalization in Cleavage Under Targets and Release Using Nuclease (CUT&RUN). CUT&RUN normalization was originally performed with carryover *E. coli* DNA from MNase preparation [1], however pure preps of enzyme require post hoc DNA spike-in. CUTANA™ *E. coli* Spike-in DNA contains sufficient material for 100-200 CUT&RUN reactions (range for high and low abundance targets).

### TECHNICAL INFORMATION

|             |                                                                       |
|-------------|-----------------------------------------------------------------------|
| Storage     | Store at 4°C. After resuspending, aliquots should be stored at -20°C. |
| Formulation | 100 ng lyophilized DNA. *NOTE: May not be visible                     |

### APPLICATION NOTES

Prior to opening, pellet DNA by quickly spinning in a benchtop microfuge. Reconstitute in 200 µL DNase free water (0.5 ng/µL). Vortex tube on all sides to ensure complete resuspension. Quick spin in benchtop microfuge prior to use.

#### Use in CUT&RUN:

See full protocol: [www.epicypher.com/protocols](http://www.epicypher.com/protocols)


1. Use with CUTANA™ pAG-MNase for ChIC/CUT&RUN (EpiCypher 15-1016), which has very low *E. coli* DNA carryover.
2. Add 1-2 µL\* (0.5-1 ng) *E. coli* Spike-in DNA directly to the Stop Buffer, which quenches calcium-mediated pAG-MNase DNA digestion. Gently vortex to mix, and add to reactions.

**\*NOTE:** Based on target abundance and antibody efficiency, the amount of *E. coli* DNA may need to be adjusted. Aim for spike-in DNA to comprise ~1% (0.2 - 5%) of total sequencing reads in on-target reactions (H3K4me3, H3K27me3) (**Figure 2**).

3. After sequencing, align reads to the reference genome of experimental samples (e.g. human) as well as to *E. coli* genome.
4. Normalize data by following recommendations in the CUT&RUN Protocol: [www.epicypher.com/protocols](http://www.epicypher.com/protocols).

### REFERENCES

- [1] Meers et al. *Elife* (2019). PMID: 31232687



**FIGURE 1 DNA gel data.** *E. coli* fragment size distribution. **Lane 1:** gDNA extracted from JM101 *E. coli* cells (200 ng). **Lane 2:** Digested and purified CUTANA™ *E. coli* Spike-in DNA (200 ng) resolved via 2% E-Gel™ EX Agarose Gel. All lanes resolved on a single gel. Migration positions of DNA molecular weight markers are indicated.

| <i>E. coli</i> Spike-in DNA | Target   | Total Reads | <i>E. coli</i> Reads | % <i>E. coli</i> Reads |
|-----------------------------|----------|-------------|----------------------|------------------------|
| 1 ng                        | IgG      | 6,777,094   | 1,660,423            | 24.5                   |
|                             | H3K4me3  | 9,673,386   | 334,597              | 3.46                   |
|                             | H3K27me3 | 9,837,020   | 32,008               | 0.33                   |

**FIGURE 2 CUT&RUN sequencing data.** CUTANA™ *E. coli* Spike-in DNA (1.0 ng) was added to CUT&RUN reactions using 500,000 K562 cells enriched for a low abundance target (H3K4me3, EpiCypher 13-0060), a high abundance target (H3K27me3, EpiCypher 13-0055), and an IgG negative control (EpiCypher 13-0042). Total numbers of paired-end sequencing reads, reads aligned to *E. coli*, and percentage of total sequencing reads aligned to *E. coli* spike-in DNA are shown. **NOTE: Spike-in DNA amount should be optimized by the end user with the goal of *E. coli* DNA comprising ~1% (0.2 - 5%) of total sequencing reads in on-target reactions (H3K4me3, H3K27me3).**